Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer

21 Feb 2020

Abstract excerpt

Mismatch repair (MMR) analysis in breast cancer may help to inform immunotherapy decisions but it lacks breast-specific guidelines. Unlike in other neoplasms, MMR protein loss shows intra-tumor heterogeneity and it is not mirrored by microsatellite instability in the breast. Additional biomarkers can improve MMR clinical testing. Phosphatase and tensin homolog (PTEN) inactivation is an early oncogenic event that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32098071
DOI: 10.3390/ijms21041461

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast CancerPMID 32098071Read ↗

Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite InstabilitySemantic proximity Read ↗

PTEN Genetic and Epigenetic Alterations Define Distinct Subgroups in North Indian Breast Cancer PatientsSemantic proximity Read ↗

The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.Semantic proximity Read ↗

Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies.Semantic proximity Read ↗

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.Semantic proximity Read ↗

Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.Semantic proximity Read ↗

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.Semantic proximity Read ↗

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.Semantic proximity Read ↗

Analysis of PTEN Methylation Patterns in Soft Tissue Sarcomas by MassARRAY SpectrometrySemantic proximity Read ↗

Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing PerspectivesSemantic proximity Read ↗

PTEN mutation spectrum in breast cancers and breast hyperplasia.Semantic proximity Read ↗

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.